HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
UCART22
This study is now recruiting.
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug"). UCART22 cells are special types of cells called T-cells that have been collected from a donor and then are genetically modified (changed). T-cells are related to your immune system, which helps to fight infection. These T-cells will be changed in a way that will allow the cells to identify and kill your tumor cells.
Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) whose disease has come back or have not responded to treatment may be eligible for this study.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 267-425-7193.
ClinicalTrials.gov Identifier
Eligibility & Criteria
IRB #:
21-018552
Official Title:
21CT012 - Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study Phase:
Phase I
Phase II
Eligible Age Range:
12 - 30 Years
Gender:
All
Visit Criteria
-Receive the study drug (UCART22)
-Avoid taking certain medications (steroids, chemotherapy agents)
-Have blood, bone marrow, spinal fluid and tumor tissue from clinical procedures used for research
-Complete Follow up visits
-Have research blood samples drawn
Leader
